- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05750030
FMT in IT-refractory HCC - FAB-HCC Pilot Study
Fecal Microbiota Transplant (FMT) Combined With Atezolizumab Plus Bevacizumab in Patients With HepatoCellular Carcinoma Who Failed to Respond to Prior Immunotherapy - the FAB-HCC Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main purpose of this phase IIa pilot study is to test the safety and efficacy of fecal microbiota transplant (FMT) combined with atezolizumab plus bevacizumab in patients who failed to respond to prior immunotherapy for advanced hepatocellular carcinoma (aHCC).
The primary objective is to assess the safety of FMT combined with atezolizumab plus bevacizumab, as measured by incidence and severity of treatment-related adverse events.
The secondary objectives are to assess the efficacy of FMT in combination with atezolizumab plus bevacizumab as measured by best radiological response, objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Furthermore, the objective is to evaluate the impact of FMT with atezolizumab plus bevacizumab on the quality of life, as assessed by EQ-5D-5L questionnaires.
Finally, this study also aims to assess the following exploratory endpoints:
- the effect of FMT on recipient gut microbiota composition, diversity, rate of change from baseline, and similarity to donor stool composition over time (compared between responders and non-responders)
- the effect of FMT on immune activity in the gut
- metagenome assemblies and functional profiling before and after FMT
- single cell analyses of circulating immune cells before and after FMT
- serum and stool metabolomic and lipidomic signatures before and after FMT
This is a phase IIa, single-center, open-label pilot study. Twelve patients suffering from advanced-stage hepatocellular carcinoma will be enrolled in this trial. The planned duration for this study are 48 months.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Matthias Pinter, MD PhD
- Phone Number: 65890 +43140400
- Email: matthias.pinter@meduniwien.ac.at
Study Contact Backup
- Name: Katharina Pomej, MD
- Phone Number: 65890 +43140400
- Email: katharina.pomej@meduniwien.ac.at
Study Locations
-
-
-
Vienna, Austria, 1090
- Recruiting
- Medical University of Vienna
-
Contact:
- Matthias Pinter, MD PhD
- Phone Number: 65890 +43140400
- Email: matthias.pinter@meduniwien.ac.at
-
Sub-Investigator:
- Katharina Pomej, MD
-
Sub-Investigator:
- Bernhard Scheiner, MD PhD
-
Sub-Investigator:
- Adrian Frick, MD
-
Sub-Investigator:
- Lorenz Balcar, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed informed consent form
- Age ≥ 18 years
- Histologically or radiologically confirmed HCC
- Patients with progressive disease (according to mRECIST) during treatment with atezolizumab/bevacizumab (without prior complete or partial response as best radiological response according to mRECIST) OR patients with stable disease as best radiological response (according to mRECIST) after the first 12 months of atezolizumab/bevacizumab treatment
- Negative HIV test
- Patients with chronic hepatitis B must be under antiviral treatment and hepatitis B DNA must be < 500 IU/mL
- Variceal status must be known and if present, adequate medical or endoscopic treatment is required
- ECOG Performance Status 0-1
- Child-Pugh class A-B8
- Adequate hematological and end-organ function, defined as follows:
- AST and ALT < 10 x ULN
- Serum bilirubin < 3.5 mg/dL
- Albumin ≥ 28 g/L
- Serum creatinine ≤ 1.5 mg/dL
- Hemoglobin ≥ 8 mg/dL
- Platelet count ≥ 50 G/L
- Leukocytes ≥ 2.5 G/L
- Patients not receiving therapeutic anticoagulation: INR ≤ 2.3 or thromboplastin time ≥ 40%
- Women of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods
- Men must agree to remain abstinent (refrain from heterosexual intercourse) or use a condom
Exclusion Criteria:
- Known fibrolamellar carcinoma or mixed cholangiocellular carcinoma
- Massive tumor progression (> 100% increase in target lesions or progression associated with significant clinical deterioration)
- Uncontrolled ascites
- Overt hepatic encephalopathy or concomitant treatment with rifaximin
- Prior allogeneic stem cell or solid organ transplantation
- Active or history of severe autoimmune disease
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
- Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to study inclusion or unstable angina
- Severe infection within 4 weeks prior to study inclusion
- Pregnant or breastfeeding women
- Treatment with systemic immunosuppressive medication with the following exceptions:
- Acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for contrast allergy)
- Mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease or asthma, or low-dose corticosteroids for adrenal insufficiency
- Significant vascular disease (e.g., peripheral arterial thrombosis) within 6 months prior to study inclusion
- Major surgery within 4 weeks prior to study inclusion or minor surgery (excluding placement of a vascular access device) within 3 days prior to study inclusion
- History of gastrointestinal fistula or perforation, or intraabdominal abscess within 6 months prior to study inclusion
- Serious, non-healing wound or active ulcer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FMT combined with Atezolizumab plus Bevacizumab
|
Single FMT from patients with HCC who responded to PD-(L)1-based immunotherapy to patients with HCC who failed to achieve complete or partial response (according to mRECIST) to atezolizumab/bevacizumab.
After single FMT, patients will continue to receive atezolizumab/bevacizumab every 21-days according to protocol.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety of atezolizumab/bevacizumab in combination with FMT, measured by incidence and severity of treatment-related adverse events, determined according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0.
Time Frame: 24 months
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy assessed by the number of study participants achieving complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) as best radiological response evaluated according to mRECIST/ RECIST v1.1 criteria.
Time Frame: 24 months
|
24 months
|
Efficacy as assessed by objective response rate (ORR) and disease control rate (DCR). Objective response is defined as either complete or partial response, while disease control rate comprises complete/partial response as well as stable disease.
Time Frame: 24 months
|
24 months
|
Efficacy as assessed by progression-free survival (PFS) and overall survival (OS).
Time Frame: 24 months
|
24 months
|
Quality of life (QoL) as assessed by the patient-reported outcome EQ-5D-5L (European Quality of Life 5 Dimensions 3 Level Version) questionnaire.
Time Frame: 24 months
|
24 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Effect of FMT on recipient gut microbiota composition, diversity (alpha and beta), rate of change from baseline and similarity to donor stool composition over time as well as comparison of responders and non-responders.
Time Frame: 24 months
|
24 months
|
Effect of FMT on immune activity in the gut by analyzing gut tissue samples with immunohistochemistry staining of immune cells of patients receiving FMT.
Time Frame: 24 months
|
24 months
|
Differences in metagenome assemblies and functional profiling using shotgun metagenomic analysis of donor and recipient stool samples before and after FMT.
Time Frame: 24 months
|
24 months
|
Differences in single cell analyses of circulating immune cells in patients before and after FMT.
Time Frame: 24 months
|
24 months
|
Differences in serum and stool metabolomic and lipidomic signatures in patients before and after FMT.
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Matthias Pinter, MD PhD, Medical University of Vienna, Internal Medicine III, Department of Gastroenterology and Hepatology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Immune Checkpoint Inhibitors
- Bevacizumab
- Atezolizumab
Other Study ID Numbers
- FAB0001
- 2022-000234-42 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaboratorsWithdrawnHepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditionsUnited States
Clinical Trials on FMT combined with Atezolizumab plus Bevacizumab
-
Asan Medical CenterSeoul National University Hospital; Hanyang University; Soon Chun Hyang UniversityRecruitingHepatocellular Carcinoma | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Stage IVKorea, Republic of
-
Sun Yat-sen UniversityCompletedHepatocellular CarcinomaChina
-
CHA UniversityRecruitingHepatocellular CarcinomaKorea, Republic of
-
CHA UniversityHoffmann-La RocheCompletedAdvanced Hepatocellular CarcinomaKorea, Republic of
-
Sun Yat-sen UniversityRecruitingHepatocellular CarcinomaChina
-
Hunan Province Tumor HospitalRecruitingNon Small Cell Lung CancerChina
-
CHA UniversityBoryung Pharmaceutical Co., LtdRecruitingAdvanced Hepatocellular CarcinomaKorea, Republic of
-
Hospital of MacerataRecruiting
-
Second Affiliated Hospital, School of Medicine,...Hebei Medical University Fourth Hospital; Zhejiang University; Cancer Hospital...Not yet recruitingUnresectable Metastatic Colorectal Cancer
-
The Second Affiliated Hospital of Shandong First...RecruitingNon-small Cell Lung CancerChina